Pfizer Inc. (PFE)
Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reports
Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on Thursday citing people with knowledge of the matter.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) closed at $24.5 in the latest trading session, marking a -1.09% move from the prior day.
Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Pfizer's Headwinds May Already Be In The Price
Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earnings, reflecting aggressive patent cliff assumptions and conservative growth projections for existing products. Pipeline and acquisition success, especially in obesity/diabetes, could drive capital appreciation, with even partial wins supporting a rerating toward historical multiples.
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.
2 Safer High-Yield Stocks That Can Pay Boomers for Life
Baby Boomers should be looking to play things a bit more cautiously as stock valuations begin to climb across the board.
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the companies said on Saturday.
Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential
Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with 10% revenue growth, 30% higher adjusted income, and raised EPS guidance, with H2 expected to be even stronger. Risks include upcoming patent expirations, high dividend payout ratio, and political pressure on drug pricing, but the company is actively managing these challenges.
Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know
Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.
What's Behind The Slump In Pfizer Stock?
Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.
Pfizer: Don't Forget About Value During AI Frenzy
Pfizer is rated a Strong Buy, offering a nearly 7% forward dividend yield, which is highly likely safe. PFE's revenue has stabilized, management is delivering cost savings, and a recent drug pricing deal with the U.S. government reduces political uncertainty. The company's improving balance sheet, aggressive R&D, and undervalued stock price support long-term upside potential, despite sector headwinds.
Pfizer CEO says US pharma industry needs to collaborate with China
Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China's, where speedy processes have vaulted it to 30% of global drug development over the past decade.
